Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Namrata Vijayvergia"'
Autor:
Eric A. Ross, Jean-Nicolas Gallant, Efrat Dotan, Harry S. Cooper, Karen Ruth, Harold A. Harvey, Miriam Kunkel, Arthur Winer, Bora Lim, Kevin P. White, Kenneth R. Korzekwa, Namrata Vijayvergia, Edward W. Wang, Jeffrey Sivik, Steven J. Cohen, Wafik S. El-Deiry, Lanlan Zhou, Igor Astaturov, Crystal S. Denlinger
Publikováno v:
Clinical Colorectal Cancer. 20:e43-e52
Background Quinacrine plus a fluoropyrimidine has in vivo efficacy against metastatic colorectal cancer (mCRC). This phase 1b trial evaluated the combination of quinacrine plus capecitabine in patients with treatment-refractory mCRC. Patients and Met
Autor:
Kerry S. Campbell, R. Katherine Alpaugh, Alexander W. MacFarlane, Ho Man Yeung, Paul F. Engstrom, Essel Dulaimi, Arvind Dasari, Namrata Vijayvergia
Publikováno v:
Cancer Immunol Immunother
High grade neuroendocrine neoplasms (G3 NENs) are rare aggressive tumors with limited treatment options. Twenty-one previously treated patients with metastatic extra-pulmonary G3 NENs were treated with pembrolizumab. Baseline tumor samples were asses
Autor:
Taymeyah Al-Toubah, Steven J. Cohen, Nicole Ross, Arvind Dasari, Efrat Dotan, Paul F. Engstrom, Michael J. Hall, Melissa M. Runyen, Namrata Vijayvergia, R. Katherine Alpaugh, Jonathan R. Strosberg, Crystal S. Denlinger, Daniel M. Halperin, Mengying Deng, Samuel Litwin
Publikováno v:
British Journal of Cancer
Background Metastatic high-grade neuroendocrine neoplasms (G3NENs) have limited treatment options after progression on platinum-based therapy. We addressed the role of Pembrolizumab in patients with previously treated metastatic G3NENs. Methods Two o
Autor:
Angelica Sonzogni, Fabrizio Bianchi, Marco Barella, Jasna Metovic, Mauro Papotti, Giuseppe Pelosi, Namrata Vijayvergia, Yulan Gong, Adriana Albini, Elisa Dama
In the gastro-entero-pancreatic (GEP) tract, neuroendocrine neoplasms (NENs) include well differentiated neuroendocrine tumors (NETs) and high-grade NE carcinomas (NECs), which are thought to make up separate and mutually exclusive tumor entities. Li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4269947b5bbb20f76337011c68dc185
http://hdl.handle.net/2318/1785942
http://hdl.handle.net/2318/1785942
Autor:
Elizabeth Handorf, Patrick McKay Boland, Karen S. Gustafson, Igor Astsaturov, Yulan Gong, Harry S. Cooper, Paul F. Engstrom, Namrata Vijayvergia, Steven J. Cohen, Fathima Sheriff
Publikováno v:
British Journal of Cancer
Background: The rarity of neuroendocrine malignancies limits the ability to develop new therapies and thus a better understanding of the underlying biology is critical. Methods: Through a prospective, IRB-approved protocol, patients with neuroendocri
Autor:
Sameer Gupta, Namrata Vijayvergia, Julianna Ricco, Kamel Hatahet, Karthik Devarajan, Bianca Lewis, Efrat Dotan, Steven J. Cohen, Farah Rahman
Publikováno v:
Journal of Geriatric Oncology. 6:454-461
Older patients with metastatic pancreatic cancer (mPC) are poorly represented in clinical trials. We compared patterns of care and outcomes of patients with mPCand65 yrs (Group 1 and Group 2, respectively) treated at Fox Chase Cancer Center (FCCC) to
Autor:
Harold A. Harvey, Joanne Xiu, Wafik S. El-Deiry, Sandeep K. Reddy, Angelique Scicchitano, Bora Lim, Namrata Vijayvergia, Zoran Gatalica, Nelson S. Yee
Publikováno v:
Cancer biologytherapy. 16(12)
Metastatic colorectal cancer (mCRC) carries a poor prognosis with an overall 5-year survival of 13.1%. Therapies guided by tumor profiling have suggested benefit in advanced cancer. We used a multiplatform molecular profiling (MP) approach to identif